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15:30 -16:00 Participants gathering 
16:00 -16:10 INTRODUCTION, Mateja Krajc 
16:10 -16:50 Cancer genetic counselling and testing in view of new treatment options/establishing new clinical pathways (Spanish experiences) 
PARP inhibitors in breast cancer. a look back and a look forward (OlympiAD trial), Judith Balmana 
16:50 - 17:40 Cancer genetic counselling and testing in view of new treatment options/establishing new clinical pathways (Belgian experiences) 
Tumor testing -where is its position in clinical pathways, Kathleen Claes 
17:40 - 18:00 DISCUSSION 
18:00 -18: 15 Coffee Break 
18:15- 19:15 HEREDITARY BREAST AND OVARIAN CANCER-SLOVENIAN EXPERIENCES 
• HBOC - germline/ somatic genetic testing - laboratory experiences (latest updates), Srdjan Novakovič
• Cancer genetic counselling -new clinical pathways in view of treatment options, Ana Blatnik, Mateja Krajc and Ksenija Strojnik
• Slovenian experiences with olaparib in ovarian cancer treatment, Erik Škof and Maja Ravnik
• PARP inhibitors in breast cancer - current and future perspectives in Slovenia, Simona Borštnar
• Surgical treatment of BRCA positive breast cancer patients - current practice and Slovenian results, Janez Žgajnar
19: 15-19:30 DISCUSSION 
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Cancer genetic counseling and 
testing in view of new treatment 
options/establishing new clinical 
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Walsh, PNAS 2011 
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BRCA-targeted approved therapies 
Olaparib (Lynparza'", AstraZeneca) 
EMA (Dec2014): Monotherapy maintenance treatment of platinum-sensitive relapsed 
BRCA-mutated (germline and/or somatic) high-grade serous ovarian cancer patients 
- FDA (Dec2014): Monotherapy for germline BRCAl/2 mutated advanced ovarian cancer 
patients who have been treated with minimum three prior lines of chemotherapy. Aug 
2017: FDA approved olaparib as maintenance treatment of patients with recurrent 
epithelial ovarian cancer who are in a response to platinum-based chemotherapy. 
Rucaparib (Rubraca'", Clovis Oncology) 
FDA (Dec2016): Monotherapy for patients with advanced ovarian cancer and 
deleterious BRCA mutation (germline and/or so matic) who have been treated 
minimum two chemotherapies. 
Niraparib (Zejula'", Tesaro) 
FDA (Mar2017): Monotherapy for maintenance treatment of patients with recurrent 
epithelial ovarian cancer, whose tumours have a response to platinum-based 
chemotherapy. 
BRCA1/2 testing 
BRCA mutations appear in: 
1 15% •5-10% 
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Ovarian Cancer Patients tested 
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BRCAl/2 testing results 
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Cancer distress reduction Genetic Counseling helpful 




Treatment implication ➔ New Genetic Counselling models 
The 'DNA-direct' model {The Netherlands) 
Telephone pretest GC IW·IME Face·to-face postest GC 
Telephone-based counselling model {USA) 
Telephone pretest GC ■:jijH@@ Telephone postest GC 
Royal Marsden testing model {UK) 
Mm __ 
Clmlcian g1ves results and 
refer to genet1cs 1f pos1t1ve 
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, Clinical validity for cancer risk assessment BRIP1, RAD51C, RAD51D
GENES CASES CONTROLS MEAN AGE RELATIVE RISK 
(95% CI) 
0.9% 63.Sy 





5.8% at 80y 
CC. 11.2 (3-34) 
BARD1 0.12% 0.06% (p=,39) 
55.5 y 
(53-60) 




NBN 0.28% 0.23% (p=.61) NA 
RAD51C 0.41% 0.07% 70% >50y 
5.2(1.1-24) 
5% at 70y 
1 
RAD51D 0.35% 0.04% 92% >50y 
12 (1.5-90) 












Memmogrephy (clinical RRSO Colono:copy Pencreatlc 
brea;t examinatlon i:creening 
and/or brea;t MRI 
Annual starting at 40* Family history' Famlly history' Clinical tria! 
Annual starting at 40tt Family history' Discussat NA 
40years 
Annual starting at 40* Family history' Family history' NA 
Annual starting at 30 Famlly history' Family hlstory' Clinlcal trial 
Family history' 50-55 years1 Family history' NA 
Tung, Nature Reviews 
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Challenges of panel testing 1 1 BRCA germline testing first for urgent therapeutics
51 ''., and 30'. of breast cancer 
patients 
at average risk and with a VUS 
or no-BRCA mutation underwent 
bilateral rnastectorny 
Kurian, JCO 2017 
� Positivo 
-Paelente'dfagnostleada0de 
cancer de ovario epitelial 
invasivo: Estudio genetico 
germinal (OM) 
� Negativo ) 
1 
� UARPC 
Panel de genes 


































































Gene panel testing first 





: �• es. de lar.ga evofucicin (platino 
sensible Q resisteote): !;;studio 
enetico somatico 
Multidisciplinary units 
PARP inhibitors in breast cancer -
a look back and a look forward 
Phase 11/111 studies with PARPi & biomarker 
analysis in breast cancer 
l. Phase II: ABRAZO- talazoparib mBC gBRCA
Cohort 1: platinum-treated(ORR 21%) 
' ' Cohort 2: platinum-nai"ve, 
but heavily pre-treated (ORR 37%) 
2. Phase III: OlympiaAD-olaparib, mBC, gBRCA
3. Phase III: BRAVO-niraparib, mBC, gBRCA






















































































Select Baseline Characteristics 
ITT Population 
ECOG = O, No. (%) 
History of CNS metastasis, No.(%) 
Visceral disease, No.(%) 



















3L+, No Prior Platinum 
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Primary Efficacy Endpoint - ORR by lndependent Radiologist Facility 
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Cohort 2 
JL+, No Prior Platinum 











Safety - Hematologic 
AII TEAEs in ;,, 15% of patients and G3+ TEAEs in ;,, 5% of patients 









Prior Platin um 








3L+, No Prior Platinum 











Safety - Nonhematologic 
AII TEAEs in ;,, 20% of patIents and G3+ TEAEs in ;,, 5% of patients 






Alopecia (grade 1) 
Back pain 
• HER2-negative metastatic BC 
- ER+ and/or PR+ or TNBC 
Deleterious or suspccted 
deleterious gBRCAm 
Prior anthracycline and taxane 
:S2 prior chemotherapy lines in 
metastatic setting 










i?:1 andocrlne therapy, or not suitable 
lf prior platinum use 
- No evidence of progression 
during treatment In the advanced 
setting 
























3L+, No Prior Platinum 
















Time to second 
progression or death 
Overall survival 
Objective response rate 







































































Age, years (median, range) 44 (22-76) 45 (24--68) 
Male,n (%) 5 (2) 2 (2) 
White race, n ('l.) 134 (65) 63(65) 
BRCA mutation status, n (%) 
BRCAi 117 (57) 51 (53) 
BRCA2 84(41) 46 (47) 
Both 4 (2) o 
Hormona! receptor status, n ('/.) 
ER+ and/or PR+ 103(50) 49(51) 
TNBC 102 (50) 48(49) 








De novo metastatic breast cancer 26 (13) 12 (12) 
Measurable disease 167(82) 
�2 sites 159(78) 
Bone metastases only 16(8) 
Prior lines of chemotherapy for metastases 
o 68(33) 31 (32) 
1 80(39) 42 (43) 
2 57(28) 24 (25) 














[ 95% CI 0.55 to 1.26 
1. -- --" 
Months 
!S, " 
ER+ and/or PR+ 









1 Olaparlb w;u; 
HR 0.43 
[_ 95%_5�1 �-�29 to ?.63 -� 
:-0 " 
TNBC 
''re!>C�l""d b·, 1/a·I( f�Cbso"1 ',l'.J (;14/X,•: ,� 
Safety summary: adverse events and exposure 
n (%) Olapanb 300 mg b d  (N•205) 
Chemotherapy TPC 
(N•91•) 
Grade 1-2 124 (60.5) 42 (46.2) 1 
75 (36.6) 
1 (0.5) 
AEs leading to drug discontinuations 10(4.9) 
AEs leading to dose reductions 52 (25.4) 
AEs leadlng to dose interruptions/delay 72 (35.1) 












Dccrcascd wh1tc blood cclls 
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Pyrcx,a 1-1- · ·· 18 







lncrcascd AST g - , ,; ■ Olapanb 300 mg bd (N•205) 
Hand-foot syndromc , 1 21 
Chcmothcrapy TPC (N=91) 
75 50 25 O 25 50 75 
Adverse events (%) 
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mutations lead to increased 
ovarian cancer risk 
BRCAl/2 somatic 
mutations are restricted to 
the neoplastic cells and 
may drive ovarian 
tumorigenesis in 
individuals without a 
germline mutation 
1 1 
Germline versus somatic mutations 
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1) 0c sp«illlttlt lVNPARZA komt voor vtreoedlna In Nl'lf'l'ICrklnc: 
indien 111 wo,clt toc:gtdicnd \'lh rnonotheraplt voor � 
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IMtst ,,krqen F)Utina bev1nende chemotheriPN tn d&t tot 
htt elndc v•n dt chtrnother• 
van 
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Belgian Journal of Medical Oncology: May 2015 
Consensus a er with Bel ian eneticists & oncolo ists 
Therapy-orienting testing of BRCA1 
and BRCA2 germline mutations in 
women with ovaria.n cancer-
l-
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BRCA.112 l•tmg 
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Cu,nrn·hc11s1,·,· NCCN Guidelines Version 1.2018 
cN·.m.:cr, BRCAMRelated Breast and/or Ovarlan Cancer Syndrome 
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NCCN Guidfl on lndex � 
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8RCA112 TESTING CRITERIA•,11 
,.._...oneormoraolfMHcttlenaw.,._1furlhel'�rlak•-IIIMffl,g,ll'le!ICtoullHll!,-g,•ndClftf11�ie1„t1ng-man...,._,., 
T"11ngofanlnclMdualwltlloul•n11ee,dl..,._1aanov1c1ontybecon1ldlftdlWMl'lanllflPJOprllM•ffKIH,_ll)'IMfflOlfl1 Llftftllllb„forWltlng, •��::"' �:.,lty wtth • known deltlfflOUI IJRCA1I • :-:·::1c:r .:r.::1:� �:= :.:Vftv
•�hltl.otyolbreHlcanc:_,-+_ormoreoflhe wttho..,.rlanc•c:lnom■•1any-s,eorbrwlle.- IBRCA l lltt 
!� S4Sy ;,����-!\'::!'�7':'::�:.:i.1 a ��=�!-�
, DwtgnoMd $!10 y wtth: ■fl'I 999 
(- tDJIO&Zl 
o M Mldltlon.l bfulf c■nce, pt111'11,y" • r�:::=c:r.
o1
11e":::,u:::-�-::.tl :�===:�� �:=:,,:•:;ur at•ny age • :..'T,•�=�='ll':;l'��-=o:;J�!�f:-.
O :t:1 l'tf•itv. wllh prottat• uncu (Oleuon 1c:or1 :t:7 o, 11 any age o, brtnt c■nclf' !ki y or two r11'1tl'tH 
IN!Htlldc:) .ithbtf:ut,p■nc,.,t1cc..,c1rorprostll1c:■nc:lf' lfcrltor1■ 
1 g���.:4:i.dflfflll'jhltlory' -��=�� �f .i::CJ!::��AM!klfl•:d !'.!'i��
A 
� ::,:::., 




lntht .i-ne1of :.,:i., th■n� 
l'nll•tt�lc) M any age • l'.,,....y hb!Of'/ oni)' (Mgr,ltle.nt Jlrnllrions of 1Hllng ICN■nlftg 
O t1 clo-■ blood „1,t1w,• wtth breHl canc:■r dl ll"Ol■d lnt■rpltlln,g 111111 rHUIII lor ■n UNllf■cad fndlotldu■I fOf' othar •• Plf' 
:S:50y 1houlclbldltci,1w,■d): hlrwdllary � 
Ot1cl0Hb4ood„IIIIY■• wtth0\larian•c■n:1nom■ 1Flf'll•or�..,,_blood"r■1at1VflfflNtlngany •� lmmtla 
O A clon m ... blood l'tfallw� wtlh bnnt c■nwr , ��.::;: C:= relatlY■ who hH b,-,11 CI� G!.ikldOII O for •n lndh,ldu•1 of athnlclty u111c: .  tfd wlth hlghlf' •Mllot ov,nan• c■rclnom■ •r,d who ,,._, t2 eloM mui.tlon l�nct (■g. A■hk■nazl J"11h) no ilddllioMI blood r■IM/Yfl� wtth brent e.tnctir JII INII OM wl\h 
1:·;i'.f!:iffe.w'="7;1 la.E�iEsf�E�---� �or c1ofW o;,,gne��,-lc�ancllftlhg. wWlflJllf!Nlron nlllolo(rf,Lr::'1'..;��bl�-==·blll --
�=��r:=•·�-�-=--�• :.=�·::=:=:-��=::-:-..=.�<1---pirrwle,l�--��ffl- M1-o!l<l•...-n...,.IIMl_,� -P"'-"l�lf:lh-•)M-<YAioncM-i."'lcliO_._, 
nrn:ni:t.1\1-•��-- ff OICf�l-...,,.,,, 
•l'ft1•0ll<IUII)' "fn'°1Jb�..-.W'del�•-1(1)IIVJldb9Pll!tMIMlllrll.,C...1!1'"fl-
"CbMtilM<i ...... ondudlhl•.- _..._419"....._"" i,eneklNlint_,.bl�#anc--.,.-Ord.dM-..�,,__,,,.....,._«W .... 
---ofwlily�) IMCA-crilena-...c.f.,._lfl<.Ulillno•lrlllln _ __...,,,.. 
http:llwww.beshg.be/downloadlguidelines/Guidelines_HBOC_2012.pdf 
BeSHG guidelines for HBOC testing 
Woman with breast cancer + one ar more of the following 
diilgnosedS3Syrs 
diilgnosed < SO yrs and one relative with bil,1ter;l l, or ovuiom, or breilst < 50, or male breast cancer 
bililterill breast aincer and both diagnosed < SO yrs 
ovilri;maincer,anyilge 
triple negative bfeut aincer < SO yrs 
three individuals with breast c�mcer, one is  il first degree relo1tive (FDR) ofthe other two (excluding mille transmitters) ilnd one di;;ignosed < 50 yeus 
individua1 of ethnicity assodated with hlgher frequency of specific mutations (eg, Ashkenilzi Jewish): eligib1e for founder mutation testing 
other family situations (eg multiple pancrHtic c;ancer) with il priori chance of mutation >10% according to BRCAPROor Evans criteriil or Manchester 
test more thiln one affected reliltive if criteria remain positive after excluding the negative case asa phenocopy 
Woman withl1igh grade serous or papillary epithelial ovarian cancer at any age (excludes borderline, low grade and 
mucinous ovarian cancer) 
Male with breast cancer 
lndividual with pancreatic cancer at any age with;?: 2 FDR excluding male transmitters with breast where one 
diagnosed 
Family history 
First degree unaffected relative of any of the above on a case by case basis 
Testing of unaffected family members should only be considered when no affected family member !s availabte and then the unaffected family 
member with the highest probability of mutation should be tesled 
So• 1, Crlteri• f,w f-11,ther C..fNflk b•lu•l6on frw 
....._. • ....,. ..,._It •nd Ovarl-.n CMKer 4> 
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■pichriial �ari■,,,, tulNil, or periton■ail aH101r M ..., ... 
-lttdCMtat'.t.SOyunorle'Mwith• llmlud 
orunk,-ilamilyhistoiy' 
- Btt.nt � and hwe lwo DI' mottl dote ret.,h,nt 
withbttilttair,no, .. .,,.,.. 
-INfltc;anc.erendlvwtwoormoredoseltl.ltlws'
wwt, p.nautk c.tnc:tl' or -a,ttM prmble unc:ef 
(Cknoo KOte cqu11l 1a or IJ'Hter thM'I 7) 
- r- bttd CMC:er pnm.r1ts, � the flrst ct.1nowd 
brioreap50ye.:. 
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tBRCA testing - workflow 
p
o
l ... ... 2 
P a l
4-6 slides
A A 10 µM 
1[� 4
'' 
>20% tumor cells 
between resection and Time 
fixation: <1 h 
Fixation tirne: 6·72h 
10% formaline 
DNA 
s · · 5x5 mm tumor reg1on. 
[ p
o





























artificial C:G > T:A SNVs 
-6 bp-,10 ndnplor - Umvorsn1 adapler 






Genetic architecture of HBOC 
BRIJ!. 
r;;::;=-i 0.001 ro=\ 
0.005 o.os i.::.:.:.::::J i!:'!.r !Low:::r:::,1 
Allete frequency 
No genetlc test (at the moment) 
Maniolo et al. Nature. 2009 Oct 8;461(7265):747·53 
Missing heritability in complex diseases 
Allcle frequency 
Manio/o et o/. Nature. 2009 Oct 8;461(7265):747-53 
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Not HR deficient BRCAl HR deficient 






CancerGenameAtlas Potentia/ for PARP inhibitors 







- Predicted to be � , this result therefore s;gojjom the diagnosis 
Prenatal testing 
i Predlctlve testlng 
Class4 
PGD 
- l.ik!tl)( pathogenic. � with the diagnosis 
Class 3 
- � pathogenicity, does not conflrm ar exdude diagnosis 
- Unsure about the pathogenicity and offer further work before offering further diagnostic or 
carner testing. 
Class 2 
- � to be pathogenic, diagnosis not confirmed molecularly. 
- No evidence suggesting pathogenicity bul not at a high enough frecuency to say it's not 
pathogenic? 
Class 1 
- Not palhogenic. 
- "Commom· polymorphism. 
- No evidence suggesting pathogenicity and at "high" frecuency. 
Classes 3, 4, 5 are reported 
Variant classification 
Purpose 1 Type of variant (source 
of DNA) 
Cancer risk assessment of a person 
+ relatives; PGD/PND 




Variant classification - precision medicine: 4 tier system 






Tier II: Varlanu of 
Potentlal Cllnlcal 
Slgnlflcance 
Ttw:raprurk. progr,osrk & 
(#ognonk 






5-tier (2, 3, 4) vs.
4-tier (5) 
Sti!INl'�l W <illllHlt.,.i f• tht l11tttp1tUtlM1 (ll­




=:-.:-..=. .... �:.::::;-,, ":,-::-.. �� ... = ...
Tler IV: Benlgn or 
Llkely Benlgn Varlanu 
■ I I -
•riv
� . 
ded to include tIe . . OT recommen rted· 1t 1s N 
. the report 
III must be re_pot5/afterations in 
Tiers I to 
vanan 
s 
Variant classification - precision medicine: 5 tier system 
ChnstftcaUon mothods for 90matlc cancer varlants 
c1a..mca11on· SVCmethod{21••J 
Clasa 1 Clnicaly_for__,..,, 
prognosdc, « dlagnoatlc pxposae for same 
tumo,type 
Cfass 2 C--for """-"k; 
prognottlc, or dlagnoltk: purpoMS for 11 
dlfferent tumor type 
Cfa,s 3 Other varianta In thls gene In thlt primaty 
tumor•e establshed as actk>nob6ofor� 
tumo, type 
Cfau4 Other variants In thls gene In this pr1ma,y 
tumor are Mtabhhec:f „ octk>nab6e for • 
different tumor typo 
Cfau5 � Gene 1s not octlonabMI lor any tumor type 
(8) Estabhhod „ be,ign 
PHIAL method 122·1 




progno1t5c, or diagno.tlc lmpllcatlons for 
same tumor type 
cairical evldence of thenpeutic r.-ponN 
trom another tumor type 
Precilnlcal asaociatlon to therapeotlc 
,..,.,., .. 
lnforenUol aasooiallon to thontpeutlc 
,..,.,., .. 
BWWDFCI • 8rfgham Women's lnstltute.lC>a.oo Fart>er Conoor Institute. 
• PHtAL method clas5lflcatlons reforred to as L..ovds A-E, whlle othor methods n,for to as Tlons. 
BWH/OFCI method 




for a diffenwrt tumor type, or llnited 
� dprognostlcordmgnoatto 
lrnplcatlons for same h.mor type 
PNolnlcalorlnf-tho<apeutio, 
prognostlc, or dlegnos,llc 
lmplcatlons 
NcNet or unsb..ded In canoer 
Ettabtlshod as benlgn 








Tumor first? Germ line first? o 







































































































HBOC-germline/ somatic genetic testing­










Since the identification and cloning of BRCAl/2 genes, according to ClinVar data base, 
more than 5000 different pathogenic or likely pathogenic mutations have been 










Five to ten percent of all breast/ovarian cancers (HBOC) are inherited, primarily due to 
mutations in BRCAl or BRCA2 genes. 
The rest of HBOC hereditary cancers are a result of mutations in other genes such as 
TP53, STK11, PTEN, CDHl, MSH2, MLHl, MSH6, PMS2, EPCAM, CHEK2, PALB2, ATM, 
RAD51c, BLM, BR/Pl, RAD51D, NBN, NFl, BARDl, MRE11A, XRCC2, ABRAXAS, CYP1A1, 
CYP17, GSTP or others. 
-*°'--
ll.lsks of Brcast. Ovarlan. and contralateral Breast cance,· 
for BRCAi and BRCA2 Mu tat Ion Carrlers 
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Results of BRCAl/2 mutation screening 1999 - december 2016 
3071 tested individuals from 2095 Slovene breast and/or ovarian cancer families 
Ratio of healthy and diseased probands among the first tested family members 
S. NOVAKOVIČ 
o 
















Results of BRCAl/2 mutation screening 1999 - december 2016 
452 BRCAl/2 positive families 
BRCAl - 318 
• BRCA2-134 










































































BRCA 1/2 mutation spectrum 1999 - december 2016 
94 different deleterious mutations: 
43 in BRCAJ 
mlssense mutatlons affecting 
the S'RING domaln 
nonsense mutations 
frame-shift mutations 
deletions of whole exons 









BRCA 1/2 mutation spectrum 1999 - december 2016 
• The most common mutation found in the BRCAl gene was 
missense mutation c.181T > G (p.Cys61Gly). It was detected in 
82 families. 
• The most common mutation in the BRCA2 gene was a splice 









Novel mutations - pathogenic variants in BRCA1 and BRCA2 




























BRCAl and BRCA2 - variants of uncertain significance (VUS) 





















NGS - genes tested in breast and ovarian cancer patients 
in 2015 - 2016 
NGS panel 2015: 
ATM, BRCAJ, BRCA2, CDHl, CHEK2, EPCAM, MLHl, MSH2, MSH6, PAL82, PMS2, PTEN, STKll, TPS3 
NGS panel 2016: 
ATM, BRCA!, BRCA2, BR/Pl, CDHl, CHEK2, EPCAM, MLHl, MSH2, MSH6, NFl, NBN, PAL82, PMS2, PTEN, RADSlC, 
RADSlD, STKll, TPS3 
Number of patients with different mutations detected with NGS in 2015 - 2016 
*in a single p�tlent mutatlons In both ORCAZ and In ATM were detected simuh�neoudy 
Reported incidenta! findings 









BRCAl/2 mutations in ovarian cancer patients in the 
period 2012-2016 
Most ovarian cancer patients have been tested for germline BRCA mutations 
Only lately have we begun to offer testing of somatic BRCA mutations 
Patients carrying germline or somatic BRCA mutation have been associated 
with a better prognosis as well as better response to platinum•based therapy 
and PARP inhibitors 
Altogether 302 tested ovarian cancer patients 
Mutations detected in 31,79% of cases 




BRCAl 76 79,17% 28 
BRCA2 20 20,83% 16 









Distribution of mutations detected with NGS in breast and 
ovarian cancer patients in 2015 - 2016 
Mutation detection rate in 2015 - 2016: 28, 70% 
S. NOVA.KOV!( 
Even though the testing focus in HBOC families is on detection of BRCA mutations, other 
highly penetrant, but less frequently mutated genes, have been recommended for testing 
Genetic testing of BRCA genes provides the key to: 
Accurate cancer risk assessment 
Effective genetic counseling 
Appropriate medica! follow-up 
Appropriate treatment 
DNA quality from FFPE tissue is a major obstacle 
lmprove analysis and interpretation by: 
o Running in duplicate 
o being careful with assay design and minimum coverage 











































































































Cancer genetic counselling -
new clinical pathways in view 
of treatment options 
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______ ., _____ __  --




___ .. _____ .... _,-,i_ .. __ 
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HBOC at the Institute of Oncology 
o 
1999 - genetic testing for BRCA genes available - in 
collaboration with Vrije Univers1teit Brussel 
2008 - all tests performed at the Institute of Oncology 
Ljubljana, state insurance covers the costs of 
counseling and testing when indicated 
2010 -management of individuals at high risk for 
breast/ ovarian cancer at our instituti on 
2011 - clinical pathways established 
2014/2015 - genetic testing performed using an NGS 
based approach (multi-gene panel) 
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1 1 
;t0tA 101' ;t016 
1999-2017: 
-500 BRCA positive families 
~additional 2-3 family members tested 
from each family 
loose testing criteria, yet a high mutation 
detection rate! 
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Olaparib asa game changer! 
o 
P ARP inhibitor olaparib approved for BRCA
mutation carriers as maintenance therapy in 
recurrent platinum sensitive OC 
in October 2014 we started offering BRCA tests to 
all ovarian cancer, fallopian tube and primary 
peritoneal serous carcinoma patients with high 
grade serous histology 
















































































Referral by the o 
treating physician Patient contacts the 
( usually medica! cancer genetic clinic -
oncologist) " appointment within 1-2 � rnooilis fumii,daW 
verification 
unnecessary! 




appropriate for Genetic testing made available to L -
, the patient relatives if indicated 
1 BRCA mutation detection rate 
o 
Mutation INoof 1% status pts 
(258) 
None 150 58.1% 
identified 
BRCA1/2 93 36.0% 
other* 15 5.8% 






























13% no contact 
(39 pts) 












































165 pts (64%) 
Negative family 
history: 
93 pts (36%) 
o 
• BRCA 1/2 mutation
detection rate: 44.8%
(74/165 pts)





Testing ali high-grade serous OC yielded an unusually 
high mutation detection rate - a higher prevalence 
of mutation carriers in the Slovene population or a 
selection bias? 
Panel testing (VUS, secondary findings, mutations in OC 
genes with no therapeutic implications) 
Adopting a modified strategy of germline testing with 
patients attending a cancer genetics clinic feasible for 
OC, but with breast cancer ... 
Tumor tissue genetic testing - pros and cons (detecting 
somatic mutations vs more limited panels)? 
Testing for defective homologous repair? 
Mutation rate in patients tested when diagnosed 
with ovarian cancer 
o 
BRCA 1/2 mutation detection rate in 
134 pts tested at the time of OC 
diagnosis 
Excluding patients with recurrent 





































































Ovarian cancer: Slovenija 
tF 
Study 19 
showed 7 months PFS* benefit of maintenance therapy with olaparib 
in patients with relapsed BRCA+ ovarian cancer1 . 
Olaparib prolonged overal survival for 4, 7 months compared to 
placebo 2 (the difference was not statistically significant). 
EMA approval of olaparib for relapsed BRCA+ ovarian cancer on 
16/12/2014 
Since 5th of february 2016 olaparib therapy is reimbursed by 
ZZZS (Health lnsurance Institute of Slovenia) for patients with 
relapsed BRCA+ ovarian cancer in Slovenia 
1. Ledefmann J et al, Lancet Oncol 201 <4 
��::.:::..�.::::: PFS" - progression-free survivat 2. Ledermann J et al. Lancet Oncol 2016 
Ovarian cancer: Slovenija 
o 
u�==
1 ncidence - 177* 
t 
• Median age - 60 years
, • Stage of disease:
• 75% advanced (FIGO IIIC/IV) 
Histology 
• ,,High-grade" serous 
(75%), 
Frequent relapses (80%) 
• 5 y OS in SLO 43%* 
"Cancer in Slovenia 2013 
Ovarian cancer: Slovenija 
t
F
• Since september 2014:
- AII patients with HGS* cancer of ovaries, fallopian tubes or
PPSC are offered to perform BRCA genetic testing at 
diagnosis 
The aim of BRCA genetic testing is: 
treatment with olaparib 
• prevention of breast and ovarian cancer 
- Active search for BRCA+ patients 
confidential data 
• multidiscplinary genetic consilium 




Olaparib experience in Slovenija 
i
l r
• Systemic therapy is applied in two lnstitutions:
Institute of Oncology Ljubljana 
University Medical centre Maribor 
• No clinical trial with olaparib in Slovenia
• First 2 pts received olaparib through „Early-access
programme" in November 2015.
• Label for olaparib is the same as in Study 19. 
[)�:�9. :=<== 
Olaparib experience in Slovenija 
• Overall 48 pts recieved therapy with olaparib
o 
- At the moment: 25 pts on treatment 
- Duralion of th: range 1-23 months (median 5 months) 
- AE - mild nausea, fatigue, anemia (G1) 
- 12 pts. had progression of the disease 
- 4 pts SAE - G3 anemia 
• 2pts continue th with reduced dose (50% dose) 
- 2 pts declined th. without evidence of AE 
li>uKc== 
ilr 
Ovarian cancer: Slovenija 
ilr 
• Current recommendations:







recommends genetic counseling 




- Waiting list for genetic counseling 
- .Highest-priority" patients wilh relapsed HGS"' ovarian cancer 
- .High-priority" patients with HGS at diagnosis 
Near future - upfront !BRCA* testing? 
- Faster results 
- Complete results - !BRCA= sBRCA+gBRCA 
<3 months 
- No need tor genetic counselling in majority (pts. and relatives) 
O !BRCA' BRCAmutation inhJmor 
HGS"" • hlgh-grade serous 
!-dKQ::= 
Olaparib experience in Slovenija 
(dala from Institute of Oncology Ljubljana) 
Median age - 60 years 
BRCA 1 - 56 years 
BRCA 2 - 63 years 
BRCA 1-70% 












































































Olaparib experience in Slovenija 
(dala tram Institute ot Oncology Ljubljana) 




1-flrll, l•UUn�. i.thlr�. MC. 
Olaparib experience in Slovenija 
(data tram Institute ot Oncology Ljubljana} 
Rtuon1ro1dl1continu1tionofolapulb 
:: 1 �:  
Cumu!.11„e 
PO)!Ctnt 








17121 patients 'Mth 1. relapse are stili on therapy 
SAE - G3 anemia (despite dose reduction) 
1-llbnu progrtnltn, 2-Atlnnt tvtnts, ,-,�tltnt rtfllnl 
o 11 
UK�!::= 
Olaparib experience in Slovenija 
(dala tram Institute ot Oncology Ljubljana} tF 
Adverse events of olaparib: 
Nausea 
• - usual� first month (metocklpramid p.p.) 
Fatigue 
1-nMISH,2-faUg11t,3anaml1, • ... 12-nausH11ndlatlg111, .. 
• - in majorily first month (? KT) 
Anemia 
• in majority G1 (no transfusion needed) 




1 plltient with dose reduction (50%) Me! disease Pf'O{Te$Sion - tnd of � 
. ''
20 






1 petlent�itedosereduction (50%)persislentG3onemia-endoftherapydue IOSAE 
UKC:== 


























































































































PARP inhibitors in breast cancer­
current and future perspectives in 
Slovenia 
Simona Borštnar 
Division of Medical Oncology 
Institute of oncology Ljubljana 






many treatment options: 
antiestrogenes, aromatase inhibitors, 
CK4/6 inhibitors, mTOR inhibitor, 
chemotherapy 
trastuzumab, pertuzumab, T-DMl, 
"' 
__ lapatinib, chemotherapy 
� few treatmentoptions: \J chemotherapy only 
Questions 
O What is the proportion of metastatic breast cancer patients suitable 
for treatment with PARP inhibitors? 
O What is current approach in the treatment of BRCA mutation 
carriers? 
O When PARP inhibitors will be available for the treatment of patients 
with breast cancer in Slovenia? 
O Are we ready to use PARP inhibitors in breast cancer? 
Overall survival of patients with metastatic breast cancer (2008-2013) 
HR+/HER2- 43.7 42.0 40.9 42.0 44.5 40.3 
(n = 9908) (40.2-46.6) (38.9-44.6) (38.0-43.4) (3926-45.04) (41.8-47.3) (37.8-NR) 
HER2 +++ 38.67 42.3 40.1 42.38 51.1 
Median NR (n = 2861) (33.6-44.6) (38.3-50.8) (35.2-45.6) (36.5-49.8) (46.5-NR) 
HR-/HER2- 15.1 15.1 14.7 14.0 13.9 14.1 
(n = 2317) (12.7-16.4) (13.0-17.4) (13.2-17.0) (11.4-15.9) (11.4-15.9) A 112.s-15.s1 
HR, hormone receptor; NR = not reached. Delaloge S, et al ASCO 2017 (Abstract 1078). 
1 
Estimated number of metastatic breast cancer (mBC) patients 








5-10% mBC pts are BRCA 1/2 positive 
' 
N:::30** 
• Estimated number of new mBC per year: primary metastatic (N ==90) and secondary metastatic (N :::300-320) 
** estimated number of BRCA positive mBC per year 
Current treatment in BRCA positive breast cancer patients 
►Traditionally, BRCA carriers have received conventional systemic
chemotherapy based on their baseline tumor characteristics.
►Tumors arising in patients with BRCA mutations were shown to be 
particularly sensitive to platinum compounds or inhibitors of PARPs.
►BRCAl-mutation carriers seem to benefit from anthracycline-taxane­
containing regimens as much as sporadic triple-negative breast cancers do.
Sikov WM et al. JCO 2015; Rugo HS et al. NEJM 2016; von Minckwitz G et al. lancet One. 2014 
Characteristics of TNBC 
►Most TNBC are invasive ductal,
minority represent medullary,
metaplastic or adenoid cystic
carcinoma.
► By gene expression profiling TNBC
are classified in two basal-like (Bll
and BL2), immunomodulatory (IM) 
and luminal androgen receptor 
(LAR) subtype. 
► Distant metastatic recurrences 
tend to occur within the first 2 to S 
years after diagnosis, late 




of ali BRCA 2 mutation carriers Narod SA. Nat Rev Ciin Oncol 2010 









EI INVESTIGATIONAL ARM 
olaparib 
veliparib+ 
temozolamide or carbo/pacli 
veliparib+ 
carbo/pacli ----













Physician choice ChT PFS 
Single arm study ORR 
Physician choice ChT PFS 
Cisplatin ORR, safety 






































































When PARP inhibitors will be available tor the treatment of patients 









�-_,,(ZZZS,_) _ � 
March 2018? • . 2019? 
Are we ready to use PARP inhibitors tor breast cancer in Slovenia? 
Genetic testing is available to all breast cancer patients who meet the 
criteria: 
► a family member with BRCA mutation 
;, diagnosis of BC under the age of 45 
>- diagnosis of TNBC under the age of 60 
).- diagnosis of two separate breast cancers {one of which was 
diagnosed under the age of 50) 
, diagnosis of breast cancer and ovarian cancer in same person 
, diagnosis of ovarian cancer 
► man with breast cancer 
► one or more close blood relatives with breast cancer that was 
diagnosed under the age of SO 
• 
It is very likely that we will have information about the BRCA mutation in 



































Surgical treatment of BRCA positive 
breast 
cancer patients - current practice 
and Slovenian results 
Strategies in BRCAl/2 mutation carriers 
• lntensive follow up




EffecUvene11 of Prophyl.ctic Su,v-rles In BRCAi 
or B»c.A2 Hut.1Uon CarrltH: A Htta•analysh .-nd 
Sy1ttm11tlc. Revlew -:s 
mutation carners. A, PBSO and breast 
canc er nsk 1n BRCAV2 mutat1on 
carners. B, PBSO and breast canccr 
risk In BRCAT mutabon carncrs. C, 
PBSO and brcast canccrnsk 1n8RCA2 
mutallon carners, The w1dth of thc 
horizontal llne rcprescnts the 95% CI I c 
of thc ind1v1dual study, and thc square 
proport10na1 represents tile we1ght 
of each study. The wrnght was 
calculatcd by th<!- sample S1Ze ol each 1 .__,_ +-
„d1vdual study, and was l)'"esented 
by the pcrcentaoc of total. The 
dklmond represents the poo!ed RR 
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f thc honzontal line rcprt-Sents thc 1 _ 
_,.,..TCOOOII ---
�0011'(tt)I ___ , 
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,.., ,nafy�s orPM and �,-ca,sc 
I 
A 
morta�ty in BRCAVl mutilt1on carncrs. -. 
A. 8PM and aU-cause mortahty m 
BRCAl/2 mulaton carrt<'l'S Wl1h no 10 
brt'ast (.}(1CCr. B, CPM aod all-causl!' 
mortaUy in BRCA1/2 rnutat,011 cerr!Cf's 
... �.CIO'I-
O..,,,jll.�,t"l,. .... ,.11 
·-
--·(Jfllt 
lne ropre,,srots thc 95"' CI ot thl!' 
!fld1vidual study, ancJ lhc SQUMI!' _ .. ..,. 
-
o 
�"- ··•·"·"•·'•�" 1 
proportooa1 rcorMl!'nls the wciqht o! 
<:::::>l each study lhe wc,gt,t was calculatcd o-4<f•00,,,,,.'••--by thc samplt- s1zc of <!'ach 1nd1vlduat 
study. and was prtscnt<!'d by thc 
�ceritagc of total Tht d..amond 
r1mrMcnts thc pool('d AR and 95%. CI 
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., •• ,, .. ti, 
f to•anllly!ls of PBSO and oll•couse 
A-rtohty In BRCAl/2 mutatton corriers, 1 PBSO and all·call'Se mortality in 
IRCAl/2 mutation c.:mitrs with no " 
riorMtory ot breast cancer. B, PBSO 
�swoe, .. 
rutatlon carriers w,th pnor history d 
rtast caocer. Tht wldth of th• ...,_. .. o:,,. 
xmzontal bne reprMtnts the 95" CI of 
• -�� __ .,. •=� 1 
he lndlvidu.ll stucty. and the SQuare o...ad'., ......... l!Ml 
roportional rePt'MeotS tht welght of 
.ach Uudy. Tht weqlt was calc\llattd 
y the samp� sile of eoch lndMdual 
·tudy. and was present� by tht 
rctnt.ige of total. The diamond 
'tprtstnts the Poo6td RR ond 95" CI. 
B 
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Table 2. Reported Rates of Uptake of RAS in the 
BRCA-Positive Population in Current Literature 
Author Dete Sampte size % RAM % Surveillance % RASO 
Uyei ..... 2006 37 24 "' 'Zl 
Kr.wn ec al. 2006 43 19 NA 78 
Frtebei,. '"- 2007 537 21 38 55 
Metcalfe et al. 2000 1,383 18 NA 49 
Bea:tUeet al. 2009 'Zl2 23 NA 51 
Kwong ec al. 2010 31 18 82 18 
Skyti!tetal 2010 306 50 NA 75 
Sdlwartz ec al. 2012 144 -.r, NA 65 
Garcia et al. 2013 305 44 NA 74 
Flippo et al 201◄ 87 44 41 46 







































































�urgical Dccision i\-taking in 1hc llllCA-Positi,·c 
l'opulmion: ln,11111111111,11 Expcncm:c anJ Cim1pari�on 
wi1h Rccc11t Li1cramrc 
1,...-...1!,rr,•·\1"""'� \IIJ,l,\l."\,• J,,.,·,1,L,ll\\".mh.(CRI'.• 
1. .ai,m, ( li.,.,,t..,,._ MD,' L.,., ,\ni.,,1n .._,,,11<, \I\, t(,._, l\<,oui. 11Clrn,, �I�. 
( (,t.· l,�n \,,1,11M1,u, Mll. �>.('>," 0,..,.,11, \I llo-·R,. \l'�! �,III 









2004 llKlli :KIOCI 3101 �OOII 20W ;:Q11;1 ;:,i,1 .'U1z .!011 .!O� �ci1s .d1w 
:O"':.-:::..�"":- :::=::=, 
Flgurw 3. R11t1111 or RAS up1ak8 as ropOflod In •oralure cw« tuno. Aegreulon on Ume Will signlflcurt 101' RAM (coeff: 3.2◄. p-value.: 
0.0287), 3nd 1'101 1or RASO (cooff; 1.134, p-v.iluo: 0.6967). 
• FEMALE,




until end of 2015 
• NO CANCER HISTORY (n= 174)
OR
• BREAST CANCER AT ANY TIME (n=232)
• PATIENTS WITH OTHER CANCER TYPES WERE EXCLUDED
RESULTS OF THE INSTITUTE OF 
ONCOLOGY LJUBLJANA 
• Evaluate the uptake of the risk reducing surgery in BRCA 1
and BRCA 2 mutation carriers in Slovenia
• Analyze the breast reconstruction rate in patients with risk
reducing mastectomy
• Comparisson oftwo periods
- Until cnd of2015 
- Yenr2016
• FEMALE,




until end of 2015 
• NO CANCER HISTORY (n= 174)
OR
• BREAST CANCER AT ANY TIME (n=232)
• PATIENTS WITH OTHER CANCER T YPES WERE EXCLUDED
3 
PATIENTS WITH BREAST 
CANCER 













N % N80% 
































BREAST RECONSTRUCTION TYPE 











































































• NO CANCER HISTORY (n= 52)
OR
• BREAST CANCER AT ANY TIME (n=S0)
• EXCLUDED 97 carriers
- 26 male patients 
- 39 ovarian cancer patienls 
- 7 Bilateral BC patients 
- 22 missing data! 
- 4 othcrs 
s 
Breast Reconstruction rate 
• Patients with BC
-33/36 92%
• Patients without BC
-8/52 15%
conclusion 
• Patients with a history of BC have a higher uptake
of risk reducing surgeries compared to patients
without cancer
• The overall risk reducing surgery uptake is
becoming higher
• Patients at hereditary risk performing PM have a
higher rate of immediate breast reconstruction
compared to patients with sporadic BC
with BC 65% 
without BC 40% 
with BC 50% 
without BC 22% 










with BC 92% 
without BC 40% o 
with BC 72% o 
without BC 15% 
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Za boljše življenje. 
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Tradicija napredka znanosti in 
medicine. Včeraj, danes in jutri. 
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